ENTERA BIO LTD. Stock-Based Compensation
ENTERA BIO LTD. (ENTX) reported Stock-Based Compensation of $1.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-07
- ENTERA BIO LTD. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $624.00K, a 22.59% increase year-over-year.
- ENTERA BIO LTD. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $672.00K, a 11.26% increase year-over-year.
- ENTERA BIO LTD. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $710.00K, a 25.44% increase year-over-year.
- ENTERA BIO LTD. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $927.00K, a 0.11% decline year-over-year.
- ENTERA BIO LTD. share-based payment arrangement, noncash expense for fiscal 2025 was $2.75M, a 7.59% increase from fiscal 2024.
- ENTERA BIO LTD. share-based payment arrangement, noncash expense for fiscal 2024 was $2.56M, a 51.33% increase from fiscal 2023.
- ENTERA BIO LTD. share-based payment arrangement, noncash expense for fiscal 2023 was $1.69M, a 24.83% decline from fiscal 2022.
- ENTERA BIO LTD. share-based payment arrangement, noncash expense for fiscal 2022 was $2.25M, a 20.74% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $624.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.30M 10-Q · filed 2026-08-07 | $2.01M derived: sum of 3 quarters · filed 2026-08-07 | $2.93M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $672.00K 10-Q · filed 2026-05-08 | $1.38M derived: sum of 2 quarters · filed 2026-05-08 | $2.31M derived: sum of 3 quarters · filed 2026-05-08 | $2.82M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $710.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.64M derived: sum of 2 quarters · filed 2026-03-27 | $2.15M derived: sum of 3 quarters · filed 2026-08-07 | $2.75M 10-K · filed 2026-03-27 |
| 2025-09-30 | $927.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.44M derived: sum of 2 quarters · filed 2026-08-07 | $2.04M 10-Q · filed 2025-11-14 | $2.61M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $509.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.11M 10-Q · filed 2026-08-07 | $1.68M derived: sum of 3 quarters · filed 2026-08-07 | $2.61M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $604.00K 10-Q · filed 2026-05-08 | $1.17M derived: sum of 2 quarters · filed 2026-05-08 | $2.10M derived: sum of 3 quarters · filed 2026-05-08 | $2.70M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $566.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.49M derived: sum of 2 quarters · filed 2026-03-27 | $2.09M derived: sum of 3 quarters · filed 2026-03-27 | $2.56M 10-K · filed 2026-03-27 |
| 2024-09-30 | $928.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.53M derived: sum of 2 quarters · filed 2025-11-14 | $1.99M 10-Q · filed 2025-11-14 | $2.31M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $598.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $1.06M 10-Q · filed 2025-08-08 | $1.38M derived: sum of 3 quarters · filed 2025-08-08 | $1.76M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $464.00K 10-Q · filed 2025-05-09 | $782.00K derived: sum of 2 quarters · filed 2025-05-09 | $1.17M derived: sum of 3 quarters · filed 2025-05-09 | $1.64M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $318.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $701.00K derived: sum of 2 quarters · filed 2025-03-28 | $1.17M derived: sum of 3 quarters · filed 2025-03-28 | $1.69M 10-K · filed 2025-03-28 |
| 2023-09-30 | $383.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $855.00K derived: sum of 2 quarters · filed 2024-11-08 | $1.37M 10-Q · filed 2024-11-08 | $1.85M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $472.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $988.00K 10-Q · filed 2024-08-09 | $1.47M derived: sum of 3 quarters · filed 2024-08-09 | $1.57M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $516.00K 10-Q · filed 2024-05-10 | $993.00K derived: sum of 2 quarters · filed 2024-05-10 | $1.10M derived: sum of 3 quarters · filed 2024-05-10 | $1.80M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $477.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $587.00K derived: sum of 2 quarters · filed 2024-03-08 | $1.28M derived: sum of 3 quarters · filed 2024-03-08 | $2.25M 10-K · filed 2024-03-08 |
| 2022-09-30 | $110.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $806.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.77M 10-Q · filed 2023-11-14 | $2.14M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $696.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $1.66M 10-Q · filed 2023-08-11 | $2.03M derived: sum of 3 quarters · filed 2023-08-11 | $2.66M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $964.00K 10-Q · filed 2023-05-05 | $1.33M derived: sum of 2 quarters · filed 2023-05-05 | $1.96M derived: sum of 3 quarters · filed 2023-05-05 | $2.50M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | $368.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $996.00K derived: sum of 2 quarters · filed 2023-03-31 | $1.53M derived: sum of 3 quarters · filed 2023-03-31 | $1.86M 10-K · filed 2023-03-31 |
| 2021-09-30 | $628.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.17M derived: sum of 2 quarters · filed 2022-11-10 | $1.49M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $538.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $865.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $327.00K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $901.00K 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |